(Q44472782)

3 December 2017

title

Safety and effectiveness of U-500 insulin therapy in patients with insulin-resistant type 2 diabetes mellitus (English)

1 reference

3 December 2017

1 reference

1 reference

1 reference

1 reference

Suzanne L Quinn

1

1 reference

3 December 2017

M Cecilia Lansang

series ordinal

2

1 reference

3 December 2017

Deanna Mina

series ordinal

3

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

3 December 2017

1 reference

3 December 2017

volume

31

1 reference

3 December 2017

issue

7

1 reference

3 December 2017

page(s)

695-702

1 reference

Prevalence and trends in obesity among US adults, 1999-2008

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

The medical complications of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

The use of U-500 in patients with extreme insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

Leptin-replacement therapy for lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

Metabolic syndrome associated with HIV and highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

Insulin sensitivity following agent orange exposure in Vietnam veterans with high blood levels of 2,3,7,8-tetrachlorodibenzo-p-dioxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is associated with hyperinsulinemia and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.7.695

21 January 2018

Identifiers

DOI

10.1592/PHCO.31.7.695

1 reference

release_upfdme5ujzgfjpc4yun4ldphk4

3 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/upfdme5ujzgfjpc4yun4ldphk4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference